MacroGenics Announces Date of Fourth Quarter 2023 Financial Results Conference Call
27 Fevereiro 2024 - 7:45PM
MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company
focused on developing, manufacturing and commercializing innovative
antibody-based therapeutics for the treatment of cancer, today
announced that the Company will release its financial results for
the fourth quarter of 2023 after the market closes on Thursday,
March 7, 2024. MacroGenics will host a conference call to discuss
the financial results and recent corporate progress on Thursday,
March 7, 2024, at 4:30 pm ET.
Conference Call Information
To participate via telephone, please register in advance at this
link. Upon registration, all telephone
participants will receive a confirmation email detailing how to
join the conference call, including the dial-in number along with a
unique passcode and registrant ID that can be used to access the
call. The listen-only webcast of the conference call can be
accessed under "Events & Presentations" in the Investor
Relations section of the Company's website at
http://ir.macrogenics.com/events.cfm. A recorded replay of the
webcast will be available shortly after the conclusion of the call
and archived on the Company's website for 30 days following the
call.
About MacroGenics, Inc.
MacroGenics (the Company) is a biopharmaceutical company focused
on developing, manufacturing and commercializing innovative
monoclonal antibody-based therapeutics for the treatment of cancer.
The Company generates its pipeline of product candidates primarily
from its proprietary suite of next-generation antibody-based
technology platforms, which have applicability across broad
therapeutic domains. The combination of MacroGenics' technology
platforms and protein engineering expertise has allowed the Company
to generate promising product candidates and enter into several
strategic collaborations with global pharmaceutical and
biotechnology companies. For more information, please see the
Company's website at www.macrogenics.com. MacroGenics and the
MacroGenics logo are trademarks or registered trademarks of
MacroGenics, Inc.
###
CONTACTS:
Jim Karrels, Senior Vice President, CFO
1-301-251-5172, info@macrogenics.com
MacroGenics (NASDAQ:MGNX)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
MacroGenics (NASDAQ:MGNX)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024